| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 09/21/2011 | CN102188382A DSPE-PEG-FA-modified nanometer paclitaxel liposome and preparation method thereof |
| 09/21/2011 | CN102188380A Double-target tumor nanoliposome and preparation method thereof |
| 09/21/2011 | CN102188373A Supersaturated self-microemulsified administration system for insoluble anti-tumor drugs, and preparation method thereof |
| 09/21/2011 | CN102188370A Resveratrol injection solution and intravenous injection |
| 09/21/2011 | CN101912221B Multipurpose traditional Chinese medicine health care drug pillow |
| 09/21/2011 | CN101804025B Aqueous solution injection for picoplatin |
| 09/21/2011 | CN101711776B Method for manufacturing activated ganoderma lucidum spore powder |
| 09/21/2011 | CN101708215B Method for extracting triterpenes from schisandra chinansis |
| 09/21/2011 | CN101700369B Combination of medicines for treating gastric and intestinal cancer |
| 09/21/2011 | CN101606963B Traditional Chinese medicine combination for enhancing disintoxication and improving dyscrasia of cancer patients |
| 09/21/2011 | CN101597289B 2-tryptophanyl-Beta-tetrahydric carboline-3-formyol amino-acid benzyl ester and preparation method and application thereof |
| 09/21/2011 | CN101554417B Quality control method of antitumor Chinese medicine composition |
| 09/21/2011 | CN101538556B Method for replicating adenovirus by way of selection and mutual compensation |
| 09/21/2011 | CN101497593B 5-hydroxy coumarin and pyranoid type coumarin compounds, synthesizing method and use |
| 09/21/2011 | CN101491511B Use of Hirsutanols A in preparing anti-tumor medicine |
| 09/21/2011 | CN101448839B A process for the preparation of a taxane derivative |
| 09/21/2011 | CN101433587B Effective component of Schisandra chinensis and preparation method thereof |
| 09/21/2011 | CN101416986B Arca extract enteric-coated capsules and manufacture method thereof |
| 09/21/2011 | CN101355969B Antiproliferative combination comprising CYC-682 and a cytotoxic agent |
| 09/21/2011 | CN101353296B Method for preparing (Z)-3'-hydroxy-3,4,4',5-tetramethoxy diphenyl ethylene from regenerative natural plant resource |
| 09/21/2011 | CN101347473B Effective component of creat and preparation and use thereof |
| 09/21/2011 | CN101346137B Combination comprising combretastatin and anticancer agents |
| 09/21/2011 | CN101288695B Preparation technique of alkaloids from Stephania tetrandra |
| 09/21/2011 | CN101283783B Edible health collocryst and its preparation method |
| 09/21/2011 | CN101270134B Method for preparing pericarpium lagenariae theine |
| 09/21/2011 | CN101225085B Phenyl urazan nitrogen nitric oxide donor 2-aniline pyrimidine derivatives, preparation method, compound containing the same and use thereof |
| 09/21/2011 | CN101165068B Monoclonal antibody for resisting HER2/ErbB2 antigen, preparation method and medicament composition thereof |
| 09/21/2011 | CN101129917B Method of preparing medicine soup for treating cancer of the lungs |
| 09/21/2011 | CN101111240B Isolation of n-butylbenzenesulfonamide, synthesis of benzenesulfonamide derivatives, and use of n-butylbenzenesulfonamide and benzenesulfonamide derivatives for the treatment of benign prostate hyperp |
| 09/21/2011 | CN101084238B Receptor selectivity lymphotoxin derivates |
| 09/20/2011 | US8022221 Aurora kinase modulators and method of use |
| 09/20/2011 | US8022219 2-hydroxymethy1-3,4,5-trihydroxy-1-(4-pentyloxybenzyl) piperidine as glucosylceramide synthase (Gcs) inhibitor |
| 09/20/2011 | US8022190 An immunomolecule containing a soluble human Major Histocompatibility Complex class I effector domain linked to an antibody targeting domain; immunotherapy; anticarcinogenic agents |
| 09/20/2011 | US8022174 C-type lectin transmembrane antigen expressed in human prostate cancer and uses therof |
| 09/20/2011 | US8022079 Methods of modulating PPAR gamma-type receptors |
| 09/20/2011 | US8022071 Nitrogenous heterocyclic compounds |
| 09/20/2011 | US8022057 MAPK/ERK kinase inhibitors |
| 09/20/2011 | US8022044 Compositions and methods for therapeutic use |
| 09/20/2011 | US8022041 Prodrug of an ICE inhibitor |
| 09/20/2011 | US8021879 Adaptor protein that binds to mammalian toll-like receptor 3 and gene thereof |
| 09/20/2011 | US8021856 Transgenic cell for use as bioreactor in production of human estrogen receptor (HER) specific monoclonal antibody for use in targeted destruction of tumor cells |
| 09/20/2011 | US8021838 Transcriptional regulation of target genes |
| 09/20/2011 | US8021693 Methods of organ regeneration using Hox11-expressing pluripotent cells |
| 09/20/2011 | US8021658 Alternative splice forms of proteins as basis for multiple therapeutic modalities |
| 09/20/2011 | CA2617957C Novel camptothecin analogues compounds, a method for the preparation thereof and pharmaceutical compositions containing said compounds |
| 09/20/2011 | CA2536632C Therapy-enhancing glucan |
| 09/20/2011 | CA2516233C 2-propylidene-19-nor-vitamin d compounds |
| 09/20/2011 | CA2515484C Modulation of insulin like growth factor i receptor expression |
| 09/20/2011 | CA2510596C Dendritic cell line |
| 09/20/2011 | CA2482512C Improved viral purification methods |
| 09/20/2011 | CA2476477C Tissue specific expression |
| 09/20/2011 | CA2476067C Carbonylamino-derivatives as novel inhibitors of histone deacetylase |
| 09/20/2011 | CA2473686C Novel cytokine zcytor17 ligand |
| 09/20/2011 | CA2467774C Solubilized topoisomerase poisons |
| 09/20/2011 | CA2462903C Beta-lactamyl vasopressin v1a antagonists |
| 09/20/2011 | CA2461812C 3-(arylamino)methylene-1,3-dihydro-2h-indol-2-ones as kinase inhibitors |
| 09/20/2011 | CA2455966C Novel imidazolidine derivatives, their preparation and their use as vla-4 antagonists |
| 09/20/2011 | CA2455328C New use of cyclolignans and new cyclolignans |
| 09/20/2011 | CA2439415C Cathepsin cysteine protease inhibitors |
| 09/20/2011 | CA2411726C Use of ingenanes in treating a pkc-related condition or disorder |
| 09/20/2011 | CA2377977C Conjugates and methods for the production thereof, and their use for transporting molecules via biological membranes |
| 09/20/2011 | CA2376485C Recombinant anti-cd40 antibody and uses thereof |
| 09/20/2011 | CA2369848C Human endogenous retrovirus in breast cancer |
| 09/20/2011 | CA2337100C Polypeptides of lymphodendritic cell adhesion molecules (ldcams) and polynucleotides encoding the same |
| 09/20/2011 | CA2329137C Novel tumor antigen useful in diagnosis and therapy of prostrate and colon cancer |
| 09/20/2011 | CA2259144C Inhibition of chronic myelogenous leukemic cell growth by liposomal-antisense oligodeoxy-nucleotides targeting to grb2 or crk1 |
| 09/20/2011 | CA2225796C Novel formulation for peptide release |
| 09/15/2011 | WO2011113065A2 Pegylated polyplexes for polynucleotide delivery |
| 09/15/2011 | WO2011113048A2 Modulation of cytokine signaling |
| 09/15/2011 | WO2011113047A2 Compositions and methods for characterizing breast cancer |
| 09/15/2011 | WO2011113041A2 Neutralization of flt3 ligand as a leukemia therapy |
| 09/15/2011 | WO2011113030A2 Human cancer micro-rna expression profiles predictive of chemo-response |
| 09/15/2011 | WO2011113005A2 Compositions and methods for combinations of oligoamines with 2-difluoromethylornithine (dfmo) |
| 09/15/2011 | WO2011112995A1 Imidazopyridines syk inhibitors |
| 09/15/2011 | WO2011112935A2 Antibody fusion proteins with disrupted heparin-binding activity |
| 09/15/2011 | WO2011112933A1 Methods for the treatment of non-hodgkin's lymphomas using lenalidomide, and gene and protein biomarkers as a predictor |
| 09/15/2011 | WO2011112915A2 Methods and compositions containing fc fusiong proteins for enhancing immune responses |
| 09/15/2011 | WO2011112902A2 Nonviral gene delivery vector iopamidol, protamine, ethiodized oil reagent (viper) |
| 09/15/2011 | WO2011112900A2 Intravenous formulations of coenzyme q10 (coq10) and methods of use thereof |
| 09/15/2011 | WO2011112896A1 Hydrated crystalline forms of n-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quinolin-4-yl}oxy)phenyl]-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
| 09/15/2011 | WO2011112889A2 β-MANNOSYLCERAMIDE AND STIMULATION OF NKT CELL ANTI-TUMOR IMMUNITY |
| 09/15/2011 | WO2011112867A1 The use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas |
| 09/15/2011 | WO2011112733A1 Carbohydrate-polyamino acid-drug conjugates |
| 09/15/2011 | WO2011112689A2 Saltz of an indazolylpyrrolotriazine |
| 09/15/2011 | WO2011112666A1 Combination anti-cancer therapy |
| 09/15/2011 | WO2011112635A1 Cdc7 kinase inhibitors and uses thereof |
| 09/15/2011 | WO2011112599A2 Immunogenic pote peptides and methods of use |
| 09/15/2011 | WO2011112566A2 Basigin binding proteins |
| 09/15/2011 | WO2011112156A1 Anti-cancer agent delivery vehicles capable of improved laoding |
| 09/15/2011 | WO2011112071A2 Synergistic effect of tocotrienols and curcumin |
| 09/15/2011 | WO2011112057A2 Novel conditionally replication-competent adenovirus and a method for producing the same |
| 09/15/2011 | WO2011111898A1 Method for preparing mycobacterial cell wall skeleton |
| 09/15/2011 | WO2011111880A1 Pharmaceutical composition for treating or preventing diseases caused by the nuclear export of gsk3, including a compound for inhibiting the nuclear export of gsk3 |
| 09/15/2011 | WO2011111715A1 Nucleic acid capable of regulating cell cycle |
| 09/15/2011 | WO2011111698A1 MONOCLONAL ANTIBODY AGAINST NECROSIS MARKER ERp29 AND USE THEREOF |
| 09/15/2011 | WO2011111694A1 Monoclonal antibody against necrosis marker prdx4 and use thereof |
| 09/15/2011 | WO2011111675A1 Novel indole derivative |
| 09/15/2011 | WO2011110866A1 Phytocannabinoids in the treatment of cancer |
| 09/15/2011 | WO2011110723A1 N-acetylhexosamine sulfur derivatives and use of same as cell tumor inhibitors |
| 09/15/2011 | WO2011110613A1 Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5) |